For example the Biogen Inc. (NASDAQ:BIIB) share price dropped 56% over five years. That's an unpleasant experience for long term holders. And it's not just long term holders hurting, because the stock ...

Shares of Stoke Therapeutics sank Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

With a "terrible" job market, empty labs, and mounting competition from China, the life sciences industry is under massive ...

Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript) Insider trades: American Express, Costco among notable names this week Sage moved to ...

The lease is one of the most significant life sciences real estate transactions in Greater Boston since the industry slowdown led to a major fall-off in demand more than two years ago. Biogen Inc ...

Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

and top talent," Biogen CEO Christopher Viehbacher said in a statement. BioMed said construction on the 16-story project will begin this year. It is the first building in the 10-acre Kendall ...

Cambridge-based biotech Biogen Idec, the maker of the multiple sclerosis drug Tysabri, linkurl:announced;http://investor.biogenidec.com/phoenix.zhtml?c=148682&p=irol ...

Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar ...

Biogen's CEO emphasized the company's commitment to Kendall Square and its goals for future biomedical innovation, with state leaders expressing their support for this significant investment in ...